LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Tre
Go back to LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Tre| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 218.86 +1.71 (0.79%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $217.15 | 52 Week High | $333.65 | |||
| Open | $221.00 | 52 Week Low | $223.02 | |||
| Day High | $222.25 | P/E | 28.02 | |||
| Day Low | $215.56 | EPS | $7.81 | |||
| Volume | 182,730 | |||||
